ritanserin has been researched along with Anankastic Personality in 5 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The selective serotonin reuptake inhibitor (SSRI) fluvoxamine has been used in an attempt to understand whether there is a biological distinction among anxiety disorders." | 7.69 | Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. ( De Leeuw, AS; den Boer, JA; van Vliet, IM; Westenberg, HG, 1995) |
| "The selective serotonin reuptake inhibitor (SSRI) fluvoxamine has been used in an attempt to understand whether there is a biological distinction among anxiety disorders." | 3.69 | Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. ( De Leeuw, AS; den Boer, JA; van Vliet, IM; Westenberg, HG, 1995) |
| " Each subject was tested two times, receiving both times the same dosage of mCPP or placebo with ritanserin or placebo pre-treatment." | 2.73 | Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. ( de Leeuw, AS; Westenberg, HG, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tucci, MC | 1 |
| Dvorkin-Gheva, A | 1 |
| Johnson, E | 1 |
| Wong, M | 1 |
| Szechtman, H | 1 |
| de Leeuw, AS | 2 |
| Westenberg, HG | 2 |
| Kaurav, BP | 1 |
| Wanjari, MM | 1 |
| Chandekar, A | 1 |
| Chauhan, NS | 1 |
| Upmanyu, N | 1 |
| den Boer, JA | 1 |
| van Vliet, IM | 1 |
| Bach, M | 1 |
| Aigner, M | 1 |
| Lenz, G | 1 |
1 trial available for ritanserin and Anankastic Personality
| Article | Year |
|---|---|
Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Hydrocortisone; Male; Middle Aged; Obsessiv | 2008 |
4 other studies available for ritanserin and Anankastic Personality
| Article | Year |
|---|---|
5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Male; Obsessive-Compulsive Disorder; Piperazin | 2015 |
Influence of Withania somnifera on obsessive compulsive disorder in mice.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Female; Male; Mice; Motor Activity; Obsessive-Co | 2012 |
Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
Topics: Anxiety Disorders; Fluvoxamine; Humans; Maprotiline; Obsessive-Compulsive Disorder; Panic; Receptors | 1995 |
Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Therapy, Combination; Female; Fluoxetine; Huma | 1997 |